Ticagrelor displays net clinical benefit in GLOBAL LEADERS
20 Sep 2019
byAudrey Abella
Subgroup evaluations of the GLOBAL LEADERS trial demonstrated the anti-ischaemic efficacy of long-term ticagrelor monotherapy relative to aspirin monotherapy in patients who had percutaneous coronary intervention (PCI). However, this occurred at the expense of bleeding in the elderly.